Taiho & Cullinan Announce Phase 1/2 Data Published
01 Jun 2025 //
PR NEWSWIRE
Cullinan, Taiho, and Taiho Oncology to Present Zipalertinib Trial
22 May 2025 //
GLOBENEWSWIRE
Cullinan to Present Zipalertinib Ph1/2 Data at ASCO Meeting
23 Apr 2025 //
GLOBENEWSWIRE
Taiho & Cullinan Zipalertinib Meets Primary Endpoint In NSCLC Trial
28 Jan 2025 //
PR NEWSWIRE
Cullinan`s Zipalertinib Shows Positive Pivotal Phase 2b REZILIENT1 Data
01 Jun 2024 //
GLOBENEWSWIRE
REZILIENT3 Global First-Line Trial of Zipalertinib Launched for NSCLC
03 Aug 2023 //
PR NEWSWIRE